Investors / filer profile

Silverman Joshua

CEO and President

active in 3 companies · 0 of 1 positions beat the S&P ~6mo later

Pro
Bought: Pro
Sold: 11
Filings: 3
Companies: 2026-01-07
Last filed

EDGAR · CIK 0001524858 ↗

Track record

How each disclosed position did against the S&P ~6 months later

The outcome curve and every position's resultPro →

-4.1%

median move per position

+7.7%

S&P 500 median, same spans

0 of 1

beat the S&P ~6mo later

Disclosed positions

Estimated from their latest filings — positions may have changed since

Estimated positions from their latest filingsPro →

Activity

Open-market buy & sell volume

BuySell

Total +$80.5K bought

All filings on record

Every Form 4 transaction we track for this filer


PMCBPharmaCyte Biotech, Inc.	Buy $33.3K · 40,000 sh	2026-01-07	—
PMCBPharmaCyte Biotech, Inc.	Buy $23.7K · 30,000 sh	2026-01-06	—
PMCBPharmaCyte Biotech, Inc.	Buy $23.5K · 30,000 sh	2026-01-05	—
PMCBPharmaCyte Biotech, Inc.	Tax $263.9K · 258,750 sh	2025-12-12	—
PMCBPharmaCyte Biotech, Inc.	Grant — · 575,000 sh	2025-12-12	—
QCLSQ/C TECHNOLOGIES, INC.	Grant — · 91,356 sh	2025-11-14	—
TAOXTAO Synergies Inc.	Tax $289.2K · 40,000 sh	2025-10-17	—
TAOXTAO Synergies Inc.	Grant — · 100,000 sh	2025-10-17	—
QCLSQ/C TECHNOLOGIES, INC.	Grant — · 8,644 sh	2025-10-03	—
TAOXTAO Synergies Inc.	Tax $131.6K · 16,768 sh	2025-06-30	—

PMCBBuy

2026-01-07 · PharmaCyte Biotech, Inc.

$33.3K

—

PMCBBuy

2026-01-06 · PharmaCyte Biotech, Inc.

$23.7K

—

PMCBBuy

2026-01-05 · PharmaCyte Biotech, Inc.

$23.5K

—

PMCBTax

2025-12-12 · PharmaCyte Biotech, Inc.

$263.9K

—

PMCBGrant

2025-12-12 · PharmaCyte Biotech, Inc.

575,000

—

QCLSGrant

2025-11-14 · Q/C TECHNOLOGIES, INC.

91,356

—

TAOXTax

2025-10-17 · TAO Synergies Inc.

$289.2K

—

TAOXGrant

2025-10-17 · TAO Synergies Inc.

100,000

—

QCLSGrant

2025-10-03 · Q/C TECHNOLOGIES, INC.

8,644

—

TAOXTax

2025-06-30 · TAO Synergies Inc.

$131.6K

—

Newest 10 of 11 filingsEvery Form 4 on record, with outcomesPro →

Outcomes measure each position — the first buy in a stock and every buy within 182 days — against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.